Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study

Table 3

Median values of the EORTC QLQ-C30 subscale and specific module CXC-24 at baseline and at 6-month follow-up.

	Baseline	6-month follow-up	value
Global health status/QoL (QL2)	50.00; 50.14–55.31]	58.33; 58.88–65.47]	0.01
Functional scales
Physical functioning (PF2)	93.33; 82.34–90.74]	93.33; 82.34–90.74]	1.0
Role functioning (RF2)	100.00; 71.67–84.74]	91.67; 72.54–85.15]	0.7
Emotional functioning (EF)	58.33; 59.96–96.78]	62.50; 62.75–78.28]	0.003
Cognitive functioning (CF)	100.00; 89.12–55.31]	100.00; 88.47–96.14]	0.16
Social functioning (SF)	50.00; 29.48–40.39]	50.00; 37.03–46.31]	<0.001
Symptom scales
Fatigue (FA)	22.22; 24.73–35.09]	22.22; 24.22–34.33]	0.18
Nausea and vomiting (NV)	0.00; 0.43–3.42]	0.00; 0.43–3.42]	1.0
Pain (PA)	16.67; 24.47–31.94]	16.67; 24.02–31.75]	0.53
Dyspnoea (DY)	0.00; 5.93–14.58]	0.00; 5.55–14.58]	0.70
Insomnia (SL)	33.33; 42.74–58.54]	33.33; 42.74–58.54]	1.0
Appetite loss (AP)	0.00; 7.08–15.99]	0.00; 7.08–15.99]	1.0
Constipation (CO)	0.00; 12.51–25.94]	0.00; 11.21–24.69]	0.16
Diarrhoea (DI)	0.00; 5.37–13.86]	0.00; 6.50–15.29]	0.16
Financial difficulties (FI)	0.00; 5.93–14.58]	0.00; 4.81–13.13]	0.32
CXC-24
Functional scale
Body image (BI)	33.33; 20.25–31.04]	33.33; 23.14–33.27]	0.01
Sexual activity (SXA)	33.33; 12.63–21.99]	33.33; 24.72–36.82]	<0.001
Sexual enjoyment (SXE)	0.00; 8.26–17.38]	16.67; 14.52–27.78]	0.01
Sexual vaginal functioning (SXV)	41.67; 39.28–50.46]	66.67; 60.44–69.37]	<0.001
Symptom scale
Symptom experience (SE)	9.09; 10.71–14.93]	9.09; 9.39–12.86]	0.001
Lymphoedema (LY)	33.33; 26.34–33.92]	33.33; 27.16–34.37]	0.56
Peripheral neuropathy (PN)	0.00; 5.79–16.00]	0.00; 4.43–13.51]	0.10
Menopausal symptoms (H)	66.67; 43.79–62.62]	66.67; 45.67–63.31]	0.92
Sexual worry (SW)	66.67; 68.96–79.75]	66.67; 46.73–63.52]	<0.001

Data are shown as median 95%, CI].